BR112012006468A2 - métodos de tratamento de inflamação - Google Patents

métodos de tratamento de inflamação

Info

Publication number
BR112012006468A2
BR112012006468A2 BR112012006468A BR112012006468A BR112012006468A2 BR 112012006468 A2 BR112012006468 A2 BR 112012006468A2 BR 112012006468 A BR112012006468 A BR 112012006468A BR 112012006468 A BR112012006468 A BR 112012006468A BR 112012006468 A2 BR112012006468 A2 BR 112012006468A2
Authority
BR
Brazil
Prior art keywords
treatment methods
inflammation treatment
methods
cxcr2
cxcr4
Prior art date
Application number
BR112012006468A
Other languages
English (en)
Portuguese (pt)
Inventor
Alma Zenecke
Benedikt Vollrath
Christian Weber
Court Turner
Joshua Robert Schultz
Jürgen Bernhagen
Sergio Duron
Original Assignee
Carolus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carolus Therapeutics Inc filed Critical Carolus Therapeutics Inc
Publication of BR112012006468A2 publication Critical patent/BR112012006468A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BR112012006468A 2009-09-23 2010-09-23 métodos de tratamento de inflamação BR112012006468A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24521409P 2009-09-23 2009-09-23
US31903910P 2010-03-30 2010-03-30
PCT/US2010/050047 WO2011038149A2 (en) 2009-09-23 2010-09-23 Methods of treating inflammation

Publications (1)

Publication Number Publication Date
BR112012006468A2 true BR112012006468A2 (pt) 2016-08-09

Family

ID=43796491

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012006468A BR112012006468A2 (pt) 2009-09-23 2010-09-23 métodos de tratamento de inflamação

Country Status (9)

Country Link
EP (1) EP2480579A4 (enExample)
KR (1) KR20120105429A (enExample)
CN (1) CN102725311A (enExample)
AU (1) AU2010298249A1 (enExample)
BR (1) BR112012006468A2 (enExample)
CA (1) CA2773978A1 (enExample)
IN (1) IN2012DN02423A (enExample)
MX (1) MX2012003514A (enExample)
WO (1) WO2011038149A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2731970B1 (en) 2011-07-15 2018-11-28 MorphoSys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
NZ702315A (en) * 2012-05-17 2016-10-28 Cyon Therapeutics Inc Methods and uses for pro protein convertase subtilisin kexin 9 (pcsk9) inhibitors
TW201605886A (zh) * 2013-11-14 2016-02-16 巴克斯特保健公司 作爲治療標靶的ｍｉｆ
CN113893252A (zh) 2016-03-11 2022-01-07 阿迪亚生命科学公司 用于治疗结晶性关节病症的cxcr-2抑制剂
MX2020013155A (es) 2018-06-05 2021-04-29 Anji Pharma Us Llc Composiciones y metodos para tratar la pancreatitis.
AU2019417313B2 (en) * 2018-12-26 2023-01-19 Colgate-Palmolive Company Biomarkers of neutrophil deregulation as diagnostic for gingivitis
KR20220166809A (ko) * 2020-03-11 2022-12-19 바이오라인알엑스 리미티드 급성 호흡곤란 증후군 및 바이러스 감염 치료를 위한 cxcr4 억제제
US20210338626A1 (en) * 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication
CN112656934A (zh) * 2021-01-22 2021-04-16 深圳市图微安创科技开发有限公司 多肽at03在治疗原发性胆汁性胆管炎药物中的应用
EP4378319A1 (en) * 2022-12-01 2024-06-05 Bioiberica, S.A.U. Composition comprising bioactive peptides
CN119318647A (zh) * 2024-08-14 2025-01-17 南方医科大学 Sb225002在制备治疗心肌梗死的药物中的应用、治疗心肌梗死的组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
WO2003072753A2 (en) * 2002-02-27 2003-09-04 Emory University Multimeric binding complexes
EP1483294B2 (en) * 2002-03-01 2019-10-30 Immunomedics, Inc. Internalizing anti-cd74 antibodies and methods of use
WO2005065328A2 (en) * 2003-12-30 2005-07-21 The United States Of America, As Represented By The Department Of Veterans Affairs Macrophage migration inhibitory factor (mif) as marker for urological inflammatory disease
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20110014141A (ko) * 2008-03-20 2011-02-10 카롤러스 테라퓨틱스, 인코포레이티드 염증을 치료하는 방법
WO2010056910A2 (en) * 2008-11-12 2010-05-20 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders

Also Published As

Publication number Publication date
MX2012003514A (es) 2012-04-19
CA2773978A1 (en) 2011-03-31
CN102725311A (zh) 2012-10-10
WO2011038149A3 (en) 2011-10-27
AU2010298249A1 (en) 2012-04-19
EP2480579A2 (en) 2012-08-01
EP2480579A4 (en) 2013-07-31
KR20120105429A (ko) 2012-09-25
WO2011038149A2 (en) 2011-03-31
IN2012DN02423A (enExample) 2015-08-21

Similar Documents

Publication Publication Date Title
BR112012006468A2 (pt) métodos de tratamento de inflamação
NI201200090A (es) Composiciones para tratar náusea y vómito centralmente mediados
WO2009117710A3 (en) Methods of treating inflammation
BRPI0910198A2 (pt) composição para administração a partir de um sítio local de um agente baseado em nucleotídeos e método para tratar um sujeito sofrendo de uma doença requerendo tratamento local com um agente baseado em nucleotídeo.
MX385174B (es) Terapia antidiabética vasoprotectora y cardioprotectora.
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
MX2010006519A (es) Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina.
MA32389B1 (fr) Methode de traitement de la dyspnee associee a une insuffisance cardiaque aigue
BRPI0713447A2 (pt) composição forma de dosagem oral sólida, e, método para o tratamento de dor
MX2015009963A (es) Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía.
AU2008232453A8 (en) Methods and compositions for reduction of side effects of therapeutic treatments
CO6531463A2 (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
WO2011020061A3 (en) Compositions and methods of for treating bipolar disorder
UA109658C2 (xx) Антитіло проти cgrp
EA201301354A1 (ru) Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
SG10201902664RA (en) Combination therapy for treating cancer
BRPI1011624A2 (pt) composição, métodos para reduzir um ou mais efeitos colaterais da terapia de glicocorticóide, e para tratar ou previnir um padrão de secreção de glicocorticóide endógeno diminuído ou interrompido em um paciente.
EA201200428A1 (ru) Композиция и способ для лечения ожирения
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112013022217A8 (pt) composição farmacêutica, método de tratamento preventivo de uma síndrome hemorrágica em um paciente com hemofilia a ou b e método de tratamento de um acidente hemorrágico em um paciente com hemofilia a ou b
BR112012006070A2 (pt) composições e métodos para tratar distúrbios convulsivos.
ES2723778T3 (es) Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos
BRPI0913665B8 (pt) composição para tratamento de pressão intraocular aumentada em um paciente, compreendendo extratos de vaccinum myrtillus e de casca de pinheiro

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: CAROLUS THERAPEUTICS, INC. (US) , CAROLUS THERAPEU

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.